

You are here: Home > Collections

Ads by Google

Devastating Market Collapse in 2011?
The man who called the market crash of 2008- and helped thousands of investors not only avoid losses but actually *make money* - has now issued an urgent warning.



Dennis Slothower warns that an unavoidable collapse in the U.S. stock market - one that could wipe out hundreds of thousands of investors - may be just days away.

Dennis's Free report reveals why this is about to happen...and what you can do to protect yourself now!

[Click here to claim your free report!](#)
BROUGHT TO YOU BY STEALTH STOCKS

RELATED ARTICLES**Indian pharma industry poised for take-off**

February 27, 2008

BPOs get new growth pill; pharma MNCs come calling

June 12, 2006

'India has immense potential to take on global pharma...

September 16, 2009

'Indian bio-pharma R&D spending could grow to \$25 bn by 2025'

PTI Jun 24, 2011, 10.22am IST

Tags: USA - India Chamber of Commerce | US - India Bio

BOSTON: India's bio-pharma sector may see a surge in R&D spending to about USD 25 billion in the next 15 years, according to a Boston Consulting Group report that said favourable policies need to be implemented to attract investment and enhance innovation in the field.

The total amount that is currently being spent on innovative discovery programmes and development in the bio-pharma sector in India is about USD 2 billion.

This amount can grow to USD 25 billion by 2025 if concerted efforts are made by various stakeholders like the government, academia and industry on developing R&D and innovation in the bio-pharma field.

Ads by Google

[15-Minute Retirement Plan](#)

Download Our Free Guide For Investors with \$500k+ Portfolios

www.fi.com

[Cogitas Consulting](#)

Biotech/Pharma CIO-level Services Experience and Results

www.cogitasconsulting.com

The investment is expected to come from multinationals, Indian industry and funding organisations ploughing money into discovery and innovation.

"The Indian government needs to implement favourable policies that enhance innovation and drive collaborations, besides addressing issues in critical building blocks like talent and infrastructure," BCG said in its position paper, titled, 'Life Sciences R&D: Changing the innovation Equation in India'.

The paper was presented here today at the US-India Bio-Pharma summit organised by the USA-India Chamber of Commerce.

"While the government has taken concrete measures over the last decade to establish an innovation ecosystem, Indian stakeholders have to accelerate their capability to enable global bio-pharma to develop an India innovation strategy," the report added.


The paper outlined recommendations for Indian service providers, academia and the pharma sector that will help boost spending in the country's bio-pharma field over the next few years.


It said Indian service providers should develop a differentiated value proposition to emerge as attractive innovation partners for global bio-pharma.





0

0



 Tweet

 Recommend

 Submit

It suggested that the Indian pharma sector transform its business model from an integrated to a network approach to develop 'nichebusters', while the academia should drive commercialisation in institutes by encouraging collaborations and entrepreneurship.

If the action programme laid out for the various stakeholders is realised, the amount of money that would subsequently be spent in the Indian bio-pharma field could be about USD 25 billion by 2025, BCG partner Bart Janssens said.